Clinical Trial Update: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection [Phase 2]

View source ↗

Summary

Open-label Phase 2 study of AB-729 with pegylated interferon alfa-2a for chronic hepatitis B has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• AB-729 (nucleos(t)ide analogue)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)

Snippet

Sponsor: Arbutus Biopharma Corporation | Conditions: Chronic Hepatitis b | Phase 2 | Status: COMPLETED